CD 3 Inhibitor - Pipeline Insight 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “CD 3 Inhibitor -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘CD 3 Inhibitor - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across CD 3 Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for CD 3 Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Key Topics Covered:
1. Report Introduction
2. CD 3 Inhibitor - Overview3. Pipeline Therapeutics4. Comparative Analysis
5. CD 3 Inhibitor Pipeline Products in Clinical Stages6. CD 3 Inhibitor Pipeline Products in Non-clinical Stages7. Therapeutic Assessment: Active Products 8. Inactive Pipeline ProductsCompanies MentionedAffimed TherapeuticsMacroGenicsRocheTolerance TherapeuticsEmergent BioSolutionsGenentechMacroGenicsNovImmune SAMicromet Inc
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3tb6ml/cd_3_inhibitor?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005349/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Oncology Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/19/2018 07:24 AM/DISC: 12/19/2018 07:24 AM